AI Article Synopsis
- Over 50% of individuals with autosomal dominant polycystic kidney disease (ADPKD) will experience kidney failure, making it the 4th leading cause of end-stage kidney disease.
- ADPKD is a systemic disorder impacting not just the kidneys, but also the liver, heart, and other organs, with some patients facing severe issues like liver enlargement or aneurysm ruptures.
- Recent advances in genetics, prognosis, and treatment strategies have enabled personalized care that can alter the disease's progression, with the review emphasizing diagnosis, kidney failure risk assessment, treatment options, blood pressure control, and genetic testing.
Article Abstract
Over 50% of people affected with autosomal dominant polycystic kidney disease (ADPKD) will develop kidney failure, making ADPKD the 4th most common cause of end-stage kidney disease. ADPKD is a systemic condition affecting the kidneys, liver, heart, vasculature, and other organ systems. A minority of patients may have severe complications such as massive hepatomegaly from a polycystic liver or rupture of an intracranial aneurysm. Recent advances in the understanding of genetics, prognosis, and treatment of this condition have allowed delivery of personalized treatment capable of changing the natural history of the disease. This review focuses on diagnosis, determining risk of kidney failure, treatment, blood pressure management, and preimplantation genetic testing related to ADPKD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.akdh.2024.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!